|
We are building a portfolio of compounds that have first-in-class and best-in-class potential through our own discovery research and clinical development initiatives.
more >
|
 |
07/22/08
Exelixis Announces August 5 Webcast of Its Second Quarter 2008 Financial Results and Business Update Conference Call
07/21/08
Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer
|
|
Seven abstracts featuring Exelixis compounds were presented at ASCO's annual meeting from May 30 to June 3. Click below for an overview of some of the key data that were presented.
more >
08/05/2008 - 05:00 PM
Q2 2008 Exelixis Earnings Conference Call
|
|
Looking for a career at Exelixis? We are looking for people to join us as we turn our vision into reality.
more >
NASDAQ: EXEL
Jul 24 2008 4:00PM
PRICE: 6.60 -0.10
VOLUME: 763632 SHARES
20 minute delay
more >
|
